ImmunoGen, Inc.
DelistedCIK 855654fmd_0ZZ396ZFTQJYW5HB1W46J0B1DPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2009 to Sep 30, 2023, 54 periods
Latest annual · FY2022
Millions- Total revenues
- 109
- Operating income
- (221)
- Net income
- (223)
- Free cash flow
- (231)
Latest quarter · Q3 FY2023
Millions- Total revenues
- 113
- Operating income
- 26
- Net income
- 31
- Free cash flow
- 1
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2019 to FY2022
- +9.8%
- Revenue, 5 yearsFY2017 to FY2022
- -1.2%
- Net income, 5 yearsFY2017 to FY2022
- n/m
ImmunoGen, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Revenue | $108.8 million | $69.9 million | +55.7% | 10-K 2023-03-01 · proof |
| Operating income | -$220.9 million | -$125.1 million | 10-K 2023-03-01 · proof | |
| Net income | -$222.9 million | -$139.3 million | 10-K 2023-03-01 · proof | |
| Cash from operating activities | -$229.8 million | -$169.4 million | 10-K 2023-03-01 · proof | |
| Free cash flow | -$231.2 million | -$170.9 million | 10-K 2023-03-01 · proof | |
| Total assets | $348.9 million | $525.8 million | -33.6% | 10-K 2023-03-01 · proof |
| Total liabilities | $193.1 million | $200.2 million | -3.5% | 10-K 2023-03-01 · proof |
| Cash and cash equivalents | $275.1 million | $478.8 million | -42.5% | 10-K 2023-03-01 · proof |
- What was ImmunoGen, Inc.'s revenue in fiscal 2022?
- ImmunoGen, Inc. reported revenue of $108.8 million for fiscal 2022 (the year ended Dec 31, 2022), against $69.9 million the year before (+55.7%). Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What was ImmunoGen, Inc.'s operating income in fiscal 2022?
- ImmunoGen, Inc. reported operating income of -$220.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$125.1 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What was ImmunoGen, Inc.'s net income in fiscal 2022?
- ImmunoGen, Inc. reported net income of -$222.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$139.3 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What was ImmunoGen, Inc.'s cash from operating activities in fiscal 2022?
- ImmunoGen, Inc. reported cash from operating activities of -$229.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$169.4 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What was ImmunoGen, Inc.'s free cash flow in fiscal 2022?
- ImmunoGen, Inc. reported free cash flow of -$231.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$170.9 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What are ImmunoGen, Inc.'s total assets?
- As of Dec 31, 2022, ImmunoGen, Inc. reported total assets of $348.9 million, against $525.8 million a year earlier (-33.6%). Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What are ImmunoGen, Inc.'s total liabilities?
- As of Dec 31, 2022, ImmunoGen, Inc. reported total liabilities of $193.1 million, against $200.2 million a year earlier (-3.5%). Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What are ImmunoGen, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, ImmunoGen, Inc. reported cash and cash equivalents of $275.1 million, against $478.8 million a year earlier (-42.5%). Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:855654&period_type=annual&limit=5"Information only, not investment advice.